CAR-T cell Awareness and Clinical Impact – Insights

mdoutlook-total-oncology-intelligence-sqHow has the 58th ASH Annual Meeting been received by the oncology community? How much does attendance at this (or other major meeting) impact the uptake of the new clinical information?

MDoutlook’s® innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 58th ASH Annual Meeting in San Diego will help you understand these questions, in addition to the specific clinical topics covered by our research.

Building on over 40 analyses covering ASH, ASCO, SABCS, ESMO and ESH for nearly a decade, this is our second report from the 2016 ASH meeting. We are proud to support the entire cancer community with this research.

This OncoPoll™ report focuses on the development of CAR-T Cell therapies for a variety of hematologic malignancies. It examines a number of target antigen + malignancy therapies in development plus some additional thoughts meaning on their impact in oncologist’s practice today (even though none are commercially available).

Our analyses of the meeting impact on US oncologists this year compares the different impact of the conference on those who attended the conference versus those who learned about the news from other sources and in some cases we highlight the differences and similarities between the attendees vs. non-attendees and separating responses by institutional setting (academic vs. community): CAR-T cell OncoPoll ASH 2016 Respondents

  • US oncologists are relatively aware of and see the development of CAR-T Cell therapies as very important to the B-lineage malignancies for which they are currently being studied. The leading CAR-T Cell approach, CD19-targeted in B-Cell acute lymphocytic leukemia, slightly leads the pack in both awareness and expected importance
  • Even though CAR-T Cell therapies are not yet commercially available, oncologists are up-to-date about them in their routine practices
    • Referral of patients to the clinical trials is common, overall averaging about 4 per respondent over the past year
    • Oncologists, especially ASH attendees, frequently are being asked about these approaches by their patients, even outside of the clinical trial setting
  • The involvement of NIH in the development of CAR-T Cell therapies is seen as a positive for US oncologists
  • Attendance at the meeting is not necessary for this new information to impact clinical practices. While initial awareness of the information may be lower, upon learning about it, the physicians who did not attend recognize the clinical importance to a similar extent as those who did attend

Download your complimentary copy of our report MDoutlook OncoPoll report from ASH 2016 on CAR-T-Cell Therapies.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review

To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136.